Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-01, Vol.390 (4), p.301-313
Hauptverfasser:	Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodriguez-Otero, Paula, Bladé, Joan, Moreau, Philippe
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Bone marrow Bortezomib Cancer therapies CD38 antigen Death Dexamethasone Dexamethasone - therapeutic use Disease Progression Hematology Humans Immunotherapy Induction therapy Inhibitor drugs Lenalidomide Leukemia Lymphoma Minimal residual disease Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Neutropenia Oncology Risk assessment Survival Targeted cancer therapy Thrombocytopenia Transplantation Treatments in Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant benefit on progression-free survival among patients with multiple myeloma.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2312054